Modular in vivo antibody–ADC click to reverse drug resistance in tumours

TL;DR — This is a biomedical/chemistry paper on in vivo bioorthogonal "click" ligation of therapeutic antibodies to antibody–drug conjugates (ADCs) to boost antitumor activity in resistant tumors; it is not AI-advancement material, so none of the AI topics apply.

• Reports a modular strategy that links clinically used therapeutic antibodies to ADCs directly in the body via bioorthogonal click chemistry.
• Claims enhanced antitumor activity in heterogeneous and treatment-resistant tumors, aimed at reversing drug resistance.
• Content is thin (title + abstract snippet only); no AI/ML methods, models, or computational results are described, hence "Other."